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ABSTRACT
Background: A polyspecific, intrathecal humoral immune
response against neurotropic viruses such as measles,
rubella and varicella zoster virus (MRZ reaction, MRZR) is
present in 80–100% of patients with multiple sclerosis
(MS), but has not to date been evaluated in patients with
neuromyelitis optica (NMO).
Aims: To evaluate whether MRZR distinguishes NMO and
MS.
Methods: 20 patients with NMO and 42 with MS were
included. The intrathecal synthesis of antibodies against
measles, rubella and varicella zoster virus was detected
by calculation of the respective antibody indices (AI).
Results: A positive MRZ reaction, as defined by a
combination of at least two positive AIs, was found in 37/
42 MS, but in only 1/20 NMO patients (p,0.0001).
Median AI values differed significantly between the
groups (p,0.0005).
Conclusions: The polyspecific antiviral humoral immune
response characteristic for MS is widely missing in NMO,
irrespective of the NMO-IgG status of the patients. Our
findings further strengthen the case for NMO being
pathologically distinct from MS.
Neuromyelitis optica (NMO, Devic syndrome) is a
severe inflammatory disorder of the CNS of
putative autoimmune aetiology, predominantly
affecting the spinal cord and optic nerves.1
Whether NMO is distinct from multiple sclerosis
(MS) or rather a variant of MS is currently under
discussion.2 3 To further elucidate this question, we
compared the antiviral, intrathecal antibody reper-
toire in MS and NMO. MS is well known to be
characterised by a polyspecific, intrathecal B cell
response against neurotropic viruses such as
measles, rubella and varicella zoster virus (MRZ
reaction, MRZR), which is detectable in 80–100%
of patients with MS.4–9 In this study, we investi-
gated whether such a reaction is also present in
NMO, and whether it might help to distinguish
between NMO and MS.
PATIENTS AND METHODS
Twenty consecutive patients, with clinically defi-
nite NMO according to Wingerchuk’s 2006 cri-
teria,10 from various university hospitals in
Germany and Italy seen between 1999 and 2007
were included. All but one patient (with brainstem
involvement at onset) also fulfilled Wingerchuk’s
1999 criteria.1 NMO-IgG was assessed by indirect
immunofluorescence, as described previously,11 in
18 patients with NMO and was positive in 11
(61%). Oligoclonal bands (OCBs) were found in 7/
20 patients (35%). The sex distribution
(men:women) was 1:3 overall and 1:4.5 in the
NMO-IgG positive subgroup. Median age was
40 years (range 19–72). Longitudinally extensive
spinal cord lesions extending >3 vertebral seg-
ments were present in all patients. Except for
severe vomiting caused by a bulbar lesion in one
patient, no history of clinical disease outside the
optic nerve or spinal cord was found. Extra-optico-
spinal MRI lesions (not fulfilling McDonald criteria
for MS12) were detectable in 7/20 patients (35%; 4/7
NMO-IgG positive) during the course of disease.
NMO followed a relapsing course in 18 patients and
was monophasic in two. Median follow-up was
39 months (range 11–288). Serum and CSF samples
were obtained 0–286 months from first myelitis
(median 2 months; ,6 months in nine patients;
.24 months in four) and 0–282 months from first
optic neuritis (median 11 months; ,6 months in
nine patients; .24 month in seven). As a control
group, MRZR results from 42 consecutive patients
with MS (28 with myelitis) from Germany were
analysed, including 29 patients with relapsing–
remitting MS (RRMS), four patients with secondary
progressive MS (SPMS) and nine patients with a
clinically isolated syndrome suggestive of MS (CIS)
at the time of lumbar puncture. Diagnosis of MS was
established according to McDonald and colleagues.12
The sex distribution was 1:3.2 (10 men, 32 women).
Median age was 34.5 years (range 18–62). Serum and
CSF samples were collected 0–294 months from first
relapse (median 13 months; ,6 months in 17
patients; .24 months in 15). All lumbar punctures
were performed for diagnostic purposes only.
Quantitative expressions of the intrathecal,
humoral immune response were based on calcula-
tion of the CSF/serum ratios of specific antiviral
IgG antibodies and total IgG (QIgG[spec] =
IgGspec[CSF]/IgGspec[serum], and QIgG[total] =
IgGtotal[CSF]/IgGtotal[serum]). Antibody levels were
determined using a commercially available enzyme
linked immunosorbent assay (Dade Behring,
Germany) according to the manufacturer’s instruc-
tions. Total IgG and total albumin concentrations
in serum and CSF were determined nephelome-
trically (BN ProSpec, Dade Behring, Germany). The
intrathecal synthesis of antibodies to M, R and Z
was detected by calculation of the corresponding
antibody indices (AI):
AI = QIgG[spec]/QIgG[total], if QIgG[total] , Qlim,
and AI = QIgG[spec]/Qlim, if QIgG[total] . Qlim.
13
The upper reference range of QIgG[total], Qlim,
was calculated according to Reiber’s formula.13. AI
values .1.5 were considered to be indicative of
intrathecal IgG production against the respective
pathogen.13
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RESULTS
A positive MRZ reaction, as defined by a combination of at least
two positive AIs, was present in 37/42 patients with MS (88%)
but in only 1/20 patients with NMO (5%) (p,0.0001, Fisher
exact test) (table 1), corresponding to a positive and negative
likelihood ratio of 17.62 (95% confidence interval (CI) 2.6 to
119.4) and 0.1 (95% CI 0.05 to 0.29), respectively.
MRZR was positive in patients with RRMS (24/29) as well as
in patients with SPMS (4/4) and, notably, also in 9/9 patients
with CIS, indicating that MRZR is present early in the disease
course. A trispecific reaction, as defined by an increased AI to all
three pathogens studied, was found in 14/29 RRMS and 6/9 CIS
patients. A bispecific reaction was present in 10/29 RRMS, 4/4
SPMS and 3/9 CIS patients. Notably, immunosuppressive
treatment seemed not to affect MRZR positivity. MRZR was
positive (46bispecific, 46trispecific) in 8/8 patients treated with
methylprednisolone, azathioprine or mitoxantrone (66RRMS,
16SPMS), or a combination of mitoxantrone, methylprediso-
lone, plasma exchange and intravenous immunoglobulin
(16SPMS), whereas all MRZR negative MS patients were
untreated at the time of lumbar puncture.
In MS, median AIs were 3.9 for M, 3.1 for R and 2.60 for Z
(mean AI 5.15, 4.60 and 4.54, respectively). Median AI in NMO
was 1.18 for M, 1.03 for R and 1.02 for Z (mean 1.25, 1.37 and
1.15, respectively) (p,0.0005, Mann–Whitney U test) (fig 1).
The only MRZR positive patient with NMO had an unusual
presentation with onset at age 72 years and no further relapses
(follow-up 39 months).
DISCUSSION
MRZR has been demonstrated to be positive in 80–100% of
patients with MS.4–8 Its specificity for MS, however, has never
been systematically evaluated in appropriate controls. In this
study, we assessed MRZR, for the first time, in patients with
NMO. We found a positive MRZ reaction, as defined by at least
two positive AIs, in 88% of our patients with MS. This is in
good agreement with earlier reports.4–8 In contrast, MRZR was
negative in 19/20 patients with NMO. Our results strengthen
the case of NMO being pathophysiologically distinct from MS2 3
and, in addition, improve the differentiation of classical MS and
NMO by routine CSF analysis.
The reason for this apparently deranged intrathecal B cell
response in MS remains elusive. As simultaneous infection with
several neurotropic viruses is unlikely and PCR for measles,
rubella and varicella zoster virus has been shown to be negative
in MRZR positive patients with MS, MRZR is thought to
represent non-specific activation (so called ‘‘bystander’’ activa-
tion) of B cells within the CNS in the absence of viral
replication, whereas in MRZR negative patients, a more
targeted immune response is discussed.4 9 13 This would be well
in line with the recent proposal of a specific antigen in some
NMO patients (ie, aquaporin-4).14 15 Consistently, MRZR is also
negative in patients with other CNS disorders characterised by
well defined antibody targets such as paraneoplastic neurologi-
cal syndromes associated with antibodies against Hu, Ri, Yo,
Ma, Ta or amphiphysin (personal observation in 34 patients, SJ,
RV), viral encephalitis or myelitis,6 8 and neuroborreliosis.16 The
hypothesis of differential ways of B cell involvement is further
supported by the finding that MRZR was also negative in OCB
positive NMO patients.
Table 1 Demographic and laboratory findings in 62 patients with neuromyelitis optica (NMO) and multiple
sclerosis (MS)
NMO MS p Value
No of patients 20 42 –
Age (years) (medium (range)) 40 (19–72) 34.5 (18–62) –
Sex (men:women) 1:3 1:3.2 –
Positive MRZ reaction 1/20 (5%) 37/42 (88%) ,0.0001*
AI M+R+Z+ 0/20 (0%) 20/42 (48%) ,0.0001*
AI M+R+ or M+R+ or M+Z+ 1/20 (5%) 17/42 (40%) ,0.001*
AI measles (AU) (median) 1.18 3.9 ,0.0005{
AI rubella (AU) (median) 1.03 3.1 ,0.0005{
AI zoster (AU) (median) 1.02 2.6 ,0.0005{
OCBs 7/20 (35%) 39/42 (93%) ,0.0001*
CSF cell count .5/ml 14/20 (70%) 35/42 (83%) NS*
Cells/ml (median (range)) 7.5 (1–96) 11.5 (0–94) NS{
QAlb, elevated 10/20 (50%) 8/42 (19%) ,0.02*
+, positive antibody index; –, negative antibody index; AI, antibody indices; AU, arbitrary units; M, measles; OCB, CSF restricted
oligoclonal bands; QAlb, albumin CSF/serum ratio (age dependent upper reference range = 4+age/15 according to Reiber and
colleagues13); R, rubella; Z, zoster.
*Fisher’s exact test (two sided); {Mann Whitney U test (two tailed).
Figure 1 Box blot graph with antibody indices (AI) for measles (M),
rubella (R) and zoster (Z) in patients with neuromyelitis optica (NMO) and
multiple sclerosis (MS). The boundary of the box closest to 0 indicates
the 25th percentile, the line within the box marks the median and the
boundary of the box farthest from zero indicates the 75th percentile.
Whiskers above and below the box indicate the 90th and 10th
percentiles. In addition, outliers (N) are shown. The broken horizontal line
indicates the upper reference limit (AI = 1.5).
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Notably, MRZR testing discriminated well between MS and
NMO, irrespective of the NMO-IgG serostatus of the patient or
brain involvement. MRZR might thus be helpful in the
differential diagnostic workup of seronegative patients with
NMO, especially in those with brain lesions which often pose a
differential diagnostic challenge. Future studies should espe-
cially address the question of whether MRZR testing allows us
to predict conversion to NMO or MS in NMO-IgG negative
patients with syndromes considered to indicate ‘‘high risk’’17 of
NMO (recurrent optic neuritis (ON), recurrent transverse
myelitis, ON with myelitis not extending three segments) and
brain involvement. In a previous study, some of us have already
shown that MRZR in patients with a first attack of ON and
two or more cerebral lesions predicts progression to definite MS
(positive predictive value 86% after 4 years).18 Well in line with
these findings, MRZR was positive in 9/9 CIS patients in our
current series. Early discrimination between MS and NMO,
however, is important as management for the two diseases
differs. Whereas immunomodulating drugs such as interferon b
or copaxone have been demonstrated to be effective in MS,
immunosuppressants such as azathioprine and rituximab seem
to be favourable in NMO19–21; patients with NMO may also be
more eligible for plasma exchange than those with MS.22
Moreover, early diagnosis and treatment has been demonstrated
to influence the long term clinical outcome in MS significantly,
and the same is probably true for NMO.23 24
It should be noted as a caveat that the rate of MRZR
positivity in a given population seems to depend on the natural
prevalence of the three viral antigens tested for, as well as on the
local vaccination coverage, and the frequency of MRZR in MS
thus might not be as high in tropical or subtropical regions as in
Europe.25
In conclusion, MRZR discriminated well between MS and
NMO in our study (n = 62), with a remarkably high sensitivity
(88%), specificity (95%) and positive likelihood ratio (17.1; 95%
CI 2.6 to 119.4), compared with a reported sensitivity of 73%,
specificity of 91% and positive likelihood ratio of 8.07 (95% CI
2.13 to 30.6) for NMO-IgG in the largest study thus far
(n = 67).17 More importantly, by demonstrating differential
ways of B cell involvement, our findings add further evidence to
the hypothesis that NMO and MS are pathologically distinct
disorders.2 3 While the humoral immune response in MS is
clonally stable, deranged towards polyspecific B cell activation
in the CSF and reminiscent of interactions with neurotropic
viruses, it is differently oriented towards the production of a
specific serum antibody (ie, NMO-IgG) with probable pathoge-
netic relevance and useful diagnostic meaning in NMO. Larger
studies are warranted to evaluate whether MRZR testing
should be included in the multidimensional approach to the
differential diagnosis of MS and NMO or its formes frustes.
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